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Ambulatory Care Survey, National Hospital Discharge Survey
etc.) in terms of data elements’ design, efﬁciency of a hierarchi-
cal structure and data integrity, data security, etc. Comparative
analysis has been conducted using a tool that aggregates ques-
tions on qualitative registries’ metrics. RESULTS: Compared to
other registries, NVDRS has a well-deﬁned goal, sufﬁcient for the
development of a PH registry (to assist the design of PH inter-
ventions for a reduction of mortality due to violent deaths).
NVDRS is a population based, conﬁdential, incident-driven, com-
puterized information system. NVDRS represents a new genera-
tion of systems with the highest level of data complexity because
of the aggregation of multiple data sources obtained from differ-
ent state agencies. NVDRS encompasses essential registry func-
tions and attributes sufﬁcient to accomplish the system’s major
goals. It has well deﬁned core elements, which allows for many
types of analysis. CONCLUSIONS: A comparative analysis of
NVDRS demonstrates that goals, design and structure of this
system promote best practices for the PH patient registries.
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OBJECTIVES: To develop a Markov model that can be cali-
brated to different countries; to facilitate country-speciﬁc eco-
nomic evaluations of a vaccine that protects against infection
with multiple human papillomavirus (HPV) types. METHODS:
We developed an Excel-based Markov model of the natural
history of HPV and cervical cancer using a cycle length of six
months for transitioning between health states (Normal, HPV,
Cervical Intraepithelial Neoplasia (CIN) 1, CIN 2, CIN 3, Cer-
vical Cancer (Stages 1 to 4), and death. Health states are strati-
ﬁed by HPV type (16, 18, 31, 45, 52, Other Oncogenic, and
Non-oncogenic). Using a lifetime simulation of 12-year old girls,
the model was calibrated to current data for two European 
countries (The Netherlands, UK (UK)). Calibration endpoints
included: 1)Age-speciﬁc HPV prevalence; 2)HPV type distribu-
tion in cervical disease; 3)Prevalence of pre-cancerous lesions;
and 4)Age-speciﬁc cervical cancer incidence and mortality.
Observed screening practices and coverage (three-yearly for UK,
ﬁve-yearly for The Netherlands) were used for calibrating to a
screened environment. Transition probabilities were varied,
within established ranges, to reproduce calibration endpoints.
RESULTS: Model-predicted outcomes correlated well with
observed data for both UK and The Netherlands. Overall, HPV
prevalence was comparable for UK (model-predicted = 7.1%;
observed = 9.6%) and The Netherlands (model-predicted =
6.4%; observed = 9.2%). Differences between countries were
observed in other endpoints, such as crude cervical cancer inci-
dence per 100,000 (UK: model-predicted = 10.4, observed =
10.2; The Netherlands: model-predicted = 8.5, observed = 8.1),
as well as cervical cancer mortality per 100,000 (UK: model-
predicted = 5.2, observed = 5.1; The Netherlands: model-
predicted = 2.8, observed = 2.9). CONCLUSIONS: A model of
the natural history of HPV and cervical cancer was successfully
calibrated to two countries. It is important to calibrate to several
epidemiological endpoints in countries so that health economic
beneﬁts of vaccine can be accurately projected in future 
cost-effectiveness analyses.
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OBJECTIVES: To conduct a structured review of the literature
to identify cost-effectiveness evaluations involving at least one 
of four biologic treatments: adalimumab, anakinra, etanercept
and inﬂiximab for the treatment of autoimmune disorders.
METHODS: A structured review of the literature was conducted
in EMBASE and PubMed from January 1995 to February 2005
to identify all relevant cost-effectiveness evaluations investigat-
ing one or more of these four treatments in autoimmune 
disorders. RESULTS: Fifteen full economic evaluations were
identiﬁed. There were 12 for rheumatoid arthritis, 2 for Crohn’s
disease, and 1 for ankylosing spondylitis. There were 5 studies
in the UK, 4 in the United States, 2 studies in Sweden, one joint
study in Sweden and in the UK, one study in France, one study
in The Netherlands and one study in Spain. The majority of eval-
uations used modeling to project the long-term cost-effectiveness
of treatments. In general, cost-effectiveness ratios were favorable
for the treatment of patients with refractory disease not respond-
ing to previous treatments whether in rheumatoid arthritis or
ankylosing spondylitis. In Crohn’s disease, biologic treatments
were not cost-effective in the treatment of perianal ﬁstulae, or
for maintenance therapy in patients with moderate to severe
active disease. Due to the high cost of these treatments, cost-
effectiveness ratios were less favorable for maintenance therapy
across diseases. CONCLUSION: Modeling the cost-effectiveness
of more expensive biologic treatments in autoimmune disorders
presents signiﬁcant challenges due to the chronic and recurring
nature of diseases such as rheumatoid arthritis, Crohn’s disease
and ankylosing spondylitis. A better understanding of these
issues will be useful to researchers developing future models for
these disease areas but also for other autoimmune disorders for
which biologic agents may be appropriate such as, for example,
ulcerative colitis, psoriasis and psoriatic arthritis.
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OBJECTIVES: To investigate factors inﬂuencing health prefer-
ence with expectancy-value model (EVM). METHODS: EVM, a
model widely used to explore underlying factors of attitudes was
applied to study health preference, which was categorized as atti-
tude in psychology. The factors include attitudinal attributes
(AAs) and external variables. AAs are measured in a sum of mul-
tiplications of one’s subjective probability (expectancy) and per-
ceived value of attributes. In one-to-one interviews, four AAs
identiﬁed in focus group discussion, namely, reduction in quality
of life (RQoL), burden to family (BTF), dependence on others
(DOO) and inability to work (ITW) were assessed using 7-point
Likert scales to measure expectancy and value of each attribute.
Health preference was measured using visual analogue scales
(VAS, range 0–100). Univariate analyses were used to identify
external variables (age, gender, ethnicity, education, housing,
marital status, and concurrent chronic diseases) that cause 
signiﬁcant difference in VAS. Multiple linear regression model
(MLR) was used to investigate the explanative power of AAs and
